DocMorris AG

LSE 0RRB.L

DocMorris AG Price to Sales Ratio (P/S) on January 14, 2025: 0.15

DocMorris AG Price to Sales Ratio (P/S) is 0.15 on January 14, 2025, a -75.91% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

DocMorris AG 52-week high Price to Sales Ratio (P/S) is 0.81 on February 12, 2024, which is 453.72% above the current Price to Sales Ratio (P/S).
DocMorris AG 52-week low Price to Sales Ratio (P/S) is 0.14 on January 13, 2025, which is -6.06% below the current Price to Sales Ratio (P/S).
DocMorris AG average Price to Sales Ratio (P/S) for the last 52 weeks is 0.45.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

LSE: 0RRB.L

DocMorris AG

CEO	Mr. Walter Hess
IPO Date	Sept. 12, 2017
Location	Switzerland
Headquarters	WalzmUehlestrasse 60
Employees	1,453
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies E-commerce Retail & Wholesale

Description

DocMorris AG operates e-commerce pharmacies and a wholesale business for medical and pharmaceutical products in Switzerland and internationally. The company offers prescription and over-the-counter medicines, consumer health products, beauty and personal care products, nutritional supplements, painkillers, and first aid products, as well as medicines management services. It also operates stationary pharmacy shops. The company sells its products directly to physicians, online mail-order pharmacies, and private individuals under the Zur Rose, PromoFarma, TeleClinic, and DocMorris brands. The company was formerly known as Zur Rose Group AG and changed its name to DocMorris AG in May 2023. DocMorris AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland.

Key trends

Past 5 years